Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Connectivity Affecting the Antidepressant REsponse (The CAARE Study)

Trial Profile

Connectivity Affecting the Antidepressant REsponse (The CAARE Study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary) ; Bupropion
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms CAARE

Most Recent Events

  • 20 Aug 2020 Status changed from recruiting to completed.
  • 19 Aug 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
  • 19 Aug 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top